Main info

Identifier:

HO102 AML

Sponsor:

HOVON

Working group party:

Leukemia

Age:

18-65

Stage:

1st Line

Echelon:

Limited Site Selection

Included patients:

890

(of 920)

Active sites:

45

(of 50)

Title:

Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)

Timeline

News

Flow

Details

Phase:

Prospective randomized Phase III study

Monitoring Type:

Not any more

Objectives:

Primary objectives
For part A of the study:

• To determine the feasibility of Clofarabine when given at three possible dose levels together with standard induction cycles I and II in patients with AML/ RAEB with IPSS≥1.5 in a prospective comparison to standard induction cycles I and II without Clofarabine.

For part B of the study:

• To evaluate the effect of Clofarabine at the selected feasible dose level when combined with remission induction chemotherapy cycles I and II as regards clinical outcome (“event-free survival”) in comparison to remission induction cycles I and II with no addition of Clofarabine in a phase III study.

Secondary objectives
For part A of the study:

• To investigate the clinical efficacy of Clofarabine in combination with remission induction chemotherapy cycles I and II with regard to complete remission rate at different dose levels of Clofarabine.

For part B of the study:

• To investigate the clinical efficacy of Clofarabine with regard to the complete remission rate, disease free survival (DFS), risk of relapse and overall survival (OS) when combined with remission induction chemotherapy cycles I and II in all patients.
• To investigate the clinical efficacy of Clofarabine when combined with remission induction chemotherapy cycles I and II in molecularly and cytogenetically distinguishable subsets with regard to the complete remission rate, disease free survival (DFS), risk of relapse and overall survival (OS).
• To investigate the tolerance and toxicity of Clofarabine in combination with remission induction chemotherapy cycles I and II.
• To assess the effect of Clofarabine on peripheral CD34 cell numbers for autologous peripheral blood transplantation.
• To determine the prognostic value of molecular markers and gene expression profiles of the leukemia assessed at diagnosis.
• To evaluate the treatment effects according minimal residual disease (MRD) measurements following therapy by standardized sampling of marrow/blood.
• To evaluate the outcome of allogeneic sibling or unrelated donor SCT and autologous SCT in cytogenetically and molecularly defined prognostic subgroups of patients.

Eligibility

Inclusion Criteria:

• Age 18-65 years, inclusive
• Subjects with
  • a cytopathologically confirmed diagnosis of AML according WHO classification (excluding acute promyelocytic leukaemia) or
  • a diagnosis of refractory anemia with excess of blasts (RAEB) and IPSS score ≥1.5 or
  • patients with therapy-related AML/RAEB or
  • patients with biphenotypic leukemia (Appendices A1 and A2).
• Adequate renal and hepatic function tests as indicated by the following laboratory values:
  • Serum creatinine ≤1.0 mg/dl (≤ 88.7 micromol/L); if serum creatinine >1.0 mg/dl (>88.7 micromol/L), then the glomerular filtration rate (GFR) must be >60 ml/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where the predicted

GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine in mg/dl)-1.154 x (age in years)-0. 203 x (0.742 if patient is female) x (1.212 if patient is black)
NOTE: if serum creatinine is measured in micromol/L, recalculate it in mg/dl according to the equation: 1 mg/dl = 88.7 micromol/L) and used above mentioned formula.

• Serum bilirubin ≤1.5 × upper limit of normal (ULN)
  • Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 × ULN
  • Alkaline phosphatase ≤ 2.5 × ULN
• WHO performance status 0, 1 or 2 (see Appendix I)
• Written informed consent

Exclusion Criteria:

*Acute promyelocytic leukaemia

• Previous treatment for AML or RAEB, except hydroxyurea
• Concurrent history active malignancy in two past years prior to diagnosis except for:
  • basal and squamous cell carcinoma of the skin
  • in situ carcinoma of the cervix
• Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etcetera),
• Cardiac dysfunction as defined by:
  • Myocardial infarction within the last 6 months of study entry, or
  • Reduced left ventricular function with an ejection fraction < 50% as measured by MUGA scan or echocardiogram (another method for measuring cardiac function is acceptable), or
  • Unstable angina, or
  • Unstable cardiac arrhythmias
• Pregnant or lactating females
• Unwilling or not capable to use effective means of birth control

Registration Details

Participating Sites

= Active hospitals

= Inactive hospitals